SCI时时刷

search
CETP Inhibitors: Should We Continue to Pursue This Pathway?
CETP Inhibitors: Should We Continue to Pursue This Pathway?
For more than 20 years there has been considerable interest in the development of pharmacological inhibitors of c...
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health
The recent rise in cardiovascular disease (CVD) deaths in the USA has sparked interest in identifying and implementing eff...
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
This forward-looking review summarizes existing evidence from cardiovascular outcome trials on cardiometabolic risk-reduct...
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of redu...
Pregnancy Loss and Cardiovascular Diseases in Women: Recent Findings and Potential Mechanisms
Pregnancy Loss and Cardiovascular Diseases in Women: Recent Findings and Potential Mechanisms
Pregnancy loss (PL) has been acknowledged by the American Heart Association as a risk factor for cardiovascular diseases (...
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke
Recent data identifies increases in young ischemic and hemorrhagic strokes. We provide a contemporary overview of current ...
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins (TRLs) or remnants are important r...
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress
Focused review of select studies presented at the 2022 European Society of Cardiology Congress. Included studies assessed ...
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice
Poor diet quality is the leading risk factor related to the overall cardiometabolic disease burden in the USA and globally...
Lp(a): a New Pathway to Target?
Lp(a): a New Pathway to Target?
Over the past decades, genetic and observational evidence has positioned lipoprotein(a) as novel important and independent...
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
To discuss evidence supporting the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) to treat obesity and their r...
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
The coronary artery calcium score is a guideline-endorsed aid for further risk stratification in the primary prevention of...
Best Practices for Designing Informative Trials Including Women
Best Practices for Designing Informative Trials Including Women
Despite mandates from funding agencies and professional societies to broaden inclusivity in medical research, women remain...
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms
To provide a systematic approach to management of the patient with statin-attributed muscle symptoms. We examined the prev...
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease
To establish genome editing as a promising therapeutic approach for the treatment and prevention of atherosclerotic cardio...
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in...
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?
Cite this articleWeiss, A.J., Lorente-Ros, M., Correa, A. et al. Correction to: Recent Advances in Stent Technology: Do Th...
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
To report on recent data about PCSK9 monoclonal antibodies and to evaluate their relevance in a nucleic acid–based t...
Bempedoic Acid: for Whom and When
Bempedoic Acid: for Whom and When
The aim of creating an orally active non-statin cholesterol-lowering drug was achieved with bempedoic acid, a small linear...
Inclisiran: How Widely and When Should We Use It?
Inclisiran: How Widely and When Should We Use It?
Plasma levels of LDL cholesterol (LDL-C) are causally associated with cardiovascular risk. Reducing LDL-C results in a dec...
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Mounting evidence continues to support the causal role of triglyceride-rich lipoproteins (TRL) in the development of ather...
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women
The intent of this review is to provide an update in polypharmacy in older adults and women with a focus on common determi...
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?
Drug-eluting stents are used in nearly all cases of percutaneous coronary revascularization and have been shown to be supe...
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned
A significant proportion of patients evaluated for chest pain have ischemia with non-obstructive coronary artery disease (...
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave
To review the current evidence regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cardiometabolic...
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide for both men and women. However, CV...
Transgender Cardiovascular Health: Practical Management for the Clinician
Transgender Cardiovascular Health: Practical Management for the Clinician
Transgender individuals represent a growing part of our population with current trends indicating that clinicians will be ...